Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations.

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

Eli Lilly's operational performance is strong ... And finally, Emgality, which serves as a humanized monoclonal antibody for those who suffer from migraines, saw a rise in revenue from $168.5 ...

AbCellera’s collaborations with major players like Eli Lilly and Moderna further validate its platform, demonstrating its ...